Bajaj Medical Patent-Cliff Exposure & CMS Drug Spending Portfolio

Bajaj Medical (US): 2 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $27.8M 2024 CMS Part D & Medicaid spend, and $1,959 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2027-01-01
2024 CMS Total Public Spend$27.8M
2024 Medicare Part D Spend$13.7M
2024 Medicaid Spend$14.1M
California HCAI SB 17 FilingsSpecialty launch notice ($1,959 intro WAC)